Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13991706 | 0.92 | HPGD (0.48) | HPGDALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL14088836 | 0.92 | HPGD (0.48) | HPGDALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL22720333 | 0.81 | HPGD (0.47) | HPGDALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL4946594 | 0.79 | ALDH1A1 (0.34) | HPGDALDH1A1 | |
| SCHEMBL14088839 | 0.78 | MEN1 (0.46) | HPGDALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL14088830 | 0.78 | MEN1 (0.46) | HPGDALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL2797597 | 0.77 | HPGD (0.44) | HPGDALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL2799529 | 0.77 | HPGD (0.44) | HPGDALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL2797599 | 0.77 | HPGD (0.44) | HPGDALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL21005590 | 0.76 | ALDH1A1 (0.46) | HPGDALDH1A1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194571-A1 | Acetylenic Piperazines as Metabotropic Glutamate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194571-A1 | Acetylenic Piperazines as Metabotropic Glutamate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| WO-2007021575-A2 | ACETYLENIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037817-A1 | Acetylenic piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037817-A1 | Acetylenic piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037817-A1 | Acetylenic piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037817-A1 | Acetylenic piperazines as metabotropic glutamate receptor antagonists | GRM1, GRM5, GRIN1 | HPGD 1872/4885ALDH1A1 564/4885MEN1 2987/4885 |
| US-20080194571-A1 | Acetylenic Piperazines as Metabotropic Glutamate Receptor Antagonists | GRM1, GRM5, GRIN1 | HPGD 1872/4885ALDH1A1 564/4885MEN1 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.